COYA Stock Forecast & Price Target

Coya Therapeutics Inc. has demonstrated significant progress in its clinical execution, as evidenced by a substantial increase in collaboration revenue, which rose to $7.9 million, largely driven by successful licensing tied to the acceptance of its investigational new drug (IND) application for COYA 302 in amyotrophic lateral sclerosis (ALS). The company reported statistically significant increases in regulatory T cell (Treg) function and numbers in recent studies, reinforcing the rationale for further development in frontotemporal dementia (FTD) and supporting its ongoing clinical programs, including the ALSTARS trial. Coya's continued investment in research and development, alongside promising translational data and mechanistic validation, indicates a strong potential for future clinical milestones and revenue generation in addressing high unmet medical needs across multiple therapeutic areas.

Coya Therapeutics Inc reported a significant increase in net losses, with a net loss of $21.2 million and an EPS of ($1.27) in 2025, which reflects a worsening financial position compared to a net loss of $14.9 million and an EPS of ($0.98) in 2024. The company's therapies may face obsolescence or competition from new treatment methods if successful, in addition to the risks associated with potential failures in securing key intellectual property that could leave the company vulnerable to patent interference and litigation costs. Furthermore, the lack of cognitive decline observed in treated patients does not compensate for the broader concerns related to market viability and ongoing financial losses.